Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study

Ítems similars

• Effects of the Cannabinoid-1 Receptor Antagonist/Inverse Agonist Rimonabant on Satiety Signaling in Overweight People with Schizophrenia: A Randomized, Double-Blind, Pilot Study
  per: Warren, Kimberly R., et al.
  Publicat: (2013)
• Rimonabant for Neurocognition in Schizophrenia: A 16-Week Double Blind Randomized Placebo Controlled Trial
  per: Boggs, Douglas L., et al.
  Publicat: (2011)
• Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder
  per: Koola, Maju Mathew, et al.
  Publicat: (2013)
• Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users
  per: Huestis, Marilyn A., et al.
  Publicat: (2007)
• The Effects of Galantamine on Psychopathology in Chronic Stable Schizophrenia
  per: Conley, Robert R., et al.
  Publicat: (2009)